Press Release

INDGN/SE/2026-27/64 29 October 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Press Release regarding financial results for the 2nd quarter and half year ended September 30, 2026 Re: Regulation 30 read-with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We wish to inform you that the Company has made a press release dated October 29, 2026, announcing the financial results for the 2nd quarter and half year ended September 30, 2026 as approved by the Board of Directors at its meeting held on October 29, 2026. A copy of the Press Release is attached for your records. This will also be posted on the company’s website at: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Press release Indegene Delivers Strong Q2 FY27 Performance, H1 USD Revenue Growth Reaches a Four-Year High Q2 INR Revenue Up 39.5% YoY, H1 FY27 USD Revenue Up 27.0% YoY Bengaluru, India, October 29, 2026: Indegene, the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026. • Revenue of ₹11,223M ($117.5M), up 39.5% YoY (27.5% YoY in $) & 5.6% QoQ (4.4% QoQ in $) • EBITDA ₹1,873M at 16.7% margin, up 32.0% YoY, & PAT ₹1,123M at 10.0% margin, up 10.0% YoY • EBITDA Margin remained largely stable despite wage hikes • Customers generating $1M+ annual revenue rose by 5 sequentially to 59, including 13 in $10M+ range • Revenue per Employee (RPE) further strengthened to $79.6K – the highest among peers Quarter ended Particulars Sep 30, Jun 30, Sep 30, 2026 2026 2025 1. Revenue from operations 11,223 10,631 8,042 2. Revenue from operations ($M) 117.5 112.5 92.2 3. YoY revenue growth from operations (%) 39.5% 39.7% 17.1% 4. EBITDA 1,873 1,795 1,419 5. EBITDA margin (%) 16.7% 16.9% 17.6% 6. Profit after tax 1,123 1,162 1,021 7. Profit margin (%) 10.0% 10.9% 12.7% “Extending our strong start to FY27, Q2 revenue grew 5.6% sequentially in INR, our fifth successive quarter above 5%. Growth was broad-based, driven by expansion across our top 5 and top 20 accounts and an increase in the number of $1 million+ clients to 59. We recorded significant deal wins in GenAI-enabled transformation and upstream engagements”, said Manish Gupta, Chairman and CEO, Indegene. “With a healthy pipeline, sustained deal momentum and favourable industry tailwinds, we expect growth and margin expansion to come together in the second half.” “Despite the annual wage increase that takes effect in our second quarter, EBITDA margin remained stable at 16.7%, a marked improvement on historical Q2 margin trends. Profit after tax grew 10% YoY to INR 1,123 million”, said Suhas Prabhu, CFO, Indegene. “With the wage increase now fully reflected in our cost base, we expect EBITDA to grow faster than revenue in the coming quarters. In addition, higher yields on our investments and lower amortization should help PAT margin expand faster than EBITDA margin.” About Indegene Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. Trusted by the world’s top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale. Indegene combines deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations. By integrating technology into how work is executed and scaled, Indegene enables life sciences organizations to deliver measurable outcomes in regulated environments. For more information, visit www.indegene.com For investor inquiries, please contact: IR@indegene.com For media inquiries, please contact: yadunandan.kv@indegene.com